BIMZELX® Shows Promising Efficacy Over SKYRIZI® in Psoriatic Arthritis Treatment

Introduction to BE BOLD Study

The BE BOLD study has unveiled remarkable insights into the effectiveness of BIMZELX® (bimekizumab-bkzx) in treating psoriatic arthritis (PsA). After 24 weeks of treatment, the data exhibited that patients receiving BIMZELX experienced notably superior joint response rates compared to those treated with SKYRIZI® (risankizumab).

Superiority of BIMZELX in Clinical Response

At Week 16, BIMZELX achieved an American College of Rheumatology’s 50% improvement criteria (ACR50) in 54.9% of participants, versus 43.8% for SKYRIZI. This trend of greater efficacy was consistently noted at subsequent time points, highlighting BIMZELX's capacity to deliver sustained clinical improvements throughout the treatment period. The results were presented at the 2026 ACR Convergence, held in Orlando, Florida.

Significance of ACR50 and Treatment Expectations

ACR50 is pivotal in assessing PsA therapies as it signifies at least a 50% improvement in tender and swollen joint counts, alongside meaningful progress in three of five additional clinical measures. Dr. Joseph F. Merola emphasized that these findings redefine treatment expectations, advocating for higher goals in therapy outcomes. He noted that BIMZELX not only surpassed the standards in joint improvements but also provided rapid relief, which is crucial for patient quality of life.

Sustainability of Treatment Effects

The study reported sustained improvements through Week 24, indicating that BIMZELX maintained better response rates across various time points. High rates of complete skin clearance, measured through the Psoriasis Area and Severity Index (PASI100), were also reported, further enhancing its profile as a robust treatment option. This included achieving PASI100 rates as early as Week 4, demonstrating the medicine's rapid efficacy.

Safety Profile Similarities and Concerns

While the overall safety profile between BIMZELX and SKYRIZI appeared comparable, an exception was noted for localized Candida infections, which were more frequently reported in the BIMZELX group. Importantly, no new safety concerns arose as the study progressed. This data reinforces the narrative that while BIMZELX presents robust benefits, patient safety remains a core consideration in treatment planning.

The Broader Impact of the BE BOLD Findings

UCB's Chief Medical Officer, Donatello Crocetta, underscored how the BE BOLD results enhance treatment expectations for individuals living with PsA. The findings suggest that clinicians should aim higher when determining treatment objectives. With a comprehensive suite of data supporting the efficacy of BIMZELX, the implications resonate throughout the psoriatic arthritis community, advocating both for innovative therapeutic strategies and a shift in patient care paradigms.

Future Directions and Presentation at ACR

The full Week 24 results will be further elaborated in an oral presentation at ACR, which showcases 18 abstracts covering UCB's immunology portfolio. This ongoing commitment to research and information dissemination aims to enrich the understanding and management of PsA and related conditions.

Conclusion

The results from the BE BOLD study are a significant advancement in psoriatic arthritis treatment, illuminating the pathway for promising therapies such as BIMZELX. As we forge ahead, the integration of such findings can lead to optimized patient outcomes and a redefined landscape for managing this chronic inflammatory condition.